Merck KGaA (NASDAQ:MKGAY) Given Average Recommendation of “Hold” by Brokerages
Merck KGaA (NASDAQ:MKGAY) has received a consensus rating of “Hold” from the seven analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $66.67.
MKGAY has been the topic of a number of research reports. HSBC Holdings plc lowered shares of Merck KGaA from a “hold” rating to a “reduce” rating in a research note on Friday, April 7th. Deutsche Bank AG lowered shares of Merck KGaA from a “buy” rating to a “hold” rating in a research report on Wednesday.
Shares of Merck KGaA (MKGAY) traded down 0.62% during midday trading on Wednesday, hitting $38.36. Merck KGaA has a 52-week low of $32.53 and a 52-week high of $42.02. The firm’s 50 day moving average is $39.80 and its 200 day moving average is $38.15. The stock has a market cap of $50.01 billion and a price-to-earnings ratio of 27.99.
Merck KGaA Company Profile
Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.